Boston Scientific (CHIX:BSXD) Cyclically Adjusted PS Ratio: (As of Jul. 24, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:BSXD Boston Scientific Corp CHIX:BSXD
67 GF Score
Price €37.64
GF Value €91.85
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Boston Scientific Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Boston Scientific  (CHIX:BSXd) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Boston Scientific Cyclically Adjusted PS Ratio Related Terms


Boston Scientific Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Boston Scientific's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Boston Scientific Cyclically Adjusted PS Ratio Chart

Boston Scientific Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.89 5.86 6.85 9.83 9.62

Boston Scientific Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.80 11.22 9.98 9.62 6.12

CHIX:BSXD vs EW, GEHC, MDT: Cyclically Adjusted PS Ratio Comparison

For the Medical Devices subindustry, Boston Scientific's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Boston Scientific Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Boston Scientific's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Boston Scientific's Cyclically Adjusted PS Ratio falls into.


CHIX:BSXD
67GF Score
Boston Scientific Corp CHIX:BSXD
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Boston Scientific Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Boston Scientific's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Boston Scientific's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=3.01/330.2130*330.2130
=3.010

Current CPI (Mar. 2026) = 330.2130.

Boston Scientific Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 1.394 241.018 1.910
201609 1.359 241.428 1.859
201612 1.501 241.432 2.053
201703 1.453 243.801 1.968
201706 1.444 244.955 1.947
201709 1.337 246.819 1.789
201712 1.458 246.524 1.953
201803 1.381 249.554 1.827
201806 1.524 251.989 1.997
201809 1.461 252.439 1.911
201812 1.601 251.233 2.104
201903 1.567 254.202 2.036
201906 1.653 256.143 2.131
201909 1.741 256.759 2.239
201912 1.849 256.974 2.376
202003 1.628 258.115 2.083
202006 1.261 257.797 1.615
202009 1.578 260.280 2.002
202012 1.560 260.474 1.978
202103 1.616 264.877 2.015
202106 1.783 271.696 2.167
202109 1.736 274.310 2.090
202112 1.927 278.802 2.282
202203 1.910 287.504 2.194
202206 2.134 296.311 2.378
202209 2.223 296.808 2.473
202212 2.121 296.797 2.360
202303 2.189 301.836 2.395
202306 2.281 305.109 2.469
202309 2.241 307.789 2.404
202312 2.313 306.746 2.490
202403 2.394 312.332 2.531
202406 2.579 314.175 2.711
202409 2.550 315.301 2.671
202412 2.923 315.605 3.058
202503 2.889 319.799 2.983
202506 2.938 322.561 3.008
202509 2.886 324.800 2.934
202512 3.018 324.054 3.075
202603 3.010 330.213 3.010

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Boston Scientific (CHIX:BSXD) Overvalued in 2026?

Based on GuruFocus' analysis, Boston Scientific stock appears to be undervalued. The current stock price of €37.64 is trading 59% below its estimated GF Value™ of €91.85. GuruFocus considers Boston Scientific to be Significantly Undervalued.

Key valuation signals for CHIX:BSXD:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €91.85 vs. price of €37.64 (59% below fair value)
  • GF Score™: 67/100 with 1 warning sign

No single metric tells the full story. See the CHIX:BSXD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Boston Scientific Business Description

Address 300 Boston Scientific Way, Marlborough, MA, USA, 01752-1234
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
67GF Score

Get the complete analysis for CHIX:BSXD

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€37.64
Price
€91.85
GF Value